Bli medlem
Bli medlem

Du är här



NattoPharma has today received a letter from Kappa in which Kappa alleges that NattoPharma appears to be in infringement with Kappa's not granted European patent application no. 15193746.3 (EP3018116) and potentially also their granted European patent no. EP-B-2346806, and Kappa requires that NattoPharma shall cease and desist from any infringing activity, and if not legal action will be initiated if the patent application is granted. The patent application and the granted patent relates to processes for the preparation of synthetic vitamin K2.

The Board has carefully assessed the letter from Kappa, and the Board is comfortable with the position of NattoPharma and that the content of Kappa's letter will not have a material negative effect on NattoPharma's operations. The Board therefore unanimously maintain its recommendation to the shareholders to not accept the Offer as it in the opinion of the Board is below the underlying values of NattoPharma. 

For more information, please contact:

Kjetil Ramsøy

CEO, NattoPharma


This information is subject to the disclosure requirements of section 5-12 of the Securities Trading Act.

Författare NattoPharma ASA

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.